MiNK Therapeutics (INKT)
NASDAQ:INKT
Want to see INKT full AI Analyst Report?
Earnings Data
Report Date
Aug 12, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.6Last Year’s EPS
-1.06Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call communicates strong scientific and early clinical momentum: context-dependent mechanistic data, an unusually long median overall survival signal in refractory gastric cancer (>23 months), initiation of a randomized 90‑patient Phase II ARDS trial with a seamless Phase II/III design, scalable off‑the‑shelf manufacturing, and partnerships that reduce dilution. Offsetting risks include a modest cash balance (~$9.5M), ongoing operating losses, the early-stage nature of much of the efficacy data (investigator trials, translational findings, case reports), and typical ARDS and trial execution risks (biologic heterogeneity, prior failures in cell therapy, logistical/geopolitical complexities). On balance, the highlights (clinical signal, trial initiation, manufacturing readiness, partnerships and planned near‑term readouts) outweigh the lowlights, but execution and financing will be critical over the next 12 months.Company Guidance
Robust Translational and Clinical Presentations
Presented data at 4 major scientific meetings (pulmonary fibrosis, AACR, ASGCT, ATS) showing coherent biology across cancer, severe lung injury, fibrosis and immune dysregulation; translational analyses demonstrate context-dependent immune outputs (TH1/tumor-killing in cancer vs restoration-oriented signaling in ARDS) from the same donor-derived agent 797 product.
Remarkable Survival Signal in Refractory Gastric Cancer
Phase II/investigator-led cohort in heavily pretreated checkpoint-refractory gastroesophageal cancer showed median overall survival extended beyond 23 months in the primary cohort (patients with historically expected survival measured in months) and several patients remain alive years after dosing.
Initiation of Randomized Phase II ARDS Trial (Seamless Phase II/III Design)
Announced initiation of a randomized Phase II trial in severe acute lung injury/ARDS (1:1 randomization, ~90 patients in the randomized Phase II portion), comparing agent 797 + standard of care vs placebo + standard of care; trial designed for rapid transition to Phase III within the protocol framework and cleared for dosing by both Ukrainian Ministry of Health and the U.S. FDA.
Clear Early Endpoints and Near-Term Data Plan
Trial endpoints include overall survival, ventilator‑free days and ICU days; company expects early readouts and to present preliminary findings in the second half of the year (H2 2026), enabling a fast go/no-go assessment.
Manufacturing Scale and Practical Off-the-Shelf Product
Donor-derived iNKT product manufactured through a scalable GMV process, able to generate billions of cells per donor, cryopreserved and delivered without HLA matching or lymphodepletion—supporting rapid deployment in real-world ICU settings and reducing operational complexity and manufacturing burn (company reports having generated material needed for majority of clinical program).
Partnerships and Non-Dilutive Support
Announced collaborations (including a program targeting pediatric cancers with a partner and work with ImmunityBio on IL-15 superagonist combinations) that provide non-dilutive support and potential downstream commercial economics; operational partnership in Ukraine supports trial execution in a real-world critical care environment.
Disciplined Financial Execution and Slight Improvement in Loss Metrics
Q1 2026 net loss of ~$2.7M ($0.57 per share) versus ~$2.8M ($0.70 per share) in Q1 2025 — net loss decreased ~3.6% and loss per share decreased ~18.6%; company reports cash runway of at least 12 months inclusive of trial activities.
INKT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
INKT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 15, 2026 | $10.51 | $10.72 | +2.00% |
Mar 31, 2026 | $10.52 | $10.53 | +0.10% |
Nov 14, 2025 | $13.22 | $12.75 | -3.56% |
Aug 14, 2025 | $17.50 | $15.32 | -12.46% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does MiNK Therapeutics (INKT) report earnings?
MiNK Therapeutics (INKT) is schdueled to report earning on Aug 12, 2026, Before Open (Confirmed).
What is MiNK Therapeutics (INKT) earnings time?
MiNK Therapeutics (INKT) earnings time is at Aug 12, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is INKT EPS forecast?
INKT EPS forecast for the fiscal quarter 2026 (Q2) is -0.6.